Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type II patients
Alterations in the synthesis or enhanced inactivation of nitric oxide (NO) and an increase in endothelin-1 production lead to an imbalance that can induce arterial hypertension. Type II diabetes is characterized by impaired endothelium-dependent vasodilation and vascular disease. NO is produced thro...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
2001
|
| Materias: | |
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| Sumario: | Alterations in the synthesis or enhanced inactivation of nitric oxide (NO) and an increase in endothelin-1 production lead to an imbalance that can induce arterial hypertension. Type II diabetes is characterized by impaired endothelium-dependent vasodilation and vascular disease. NO is produced through L-arginine pathway by three different isoforms of nitric oxide synthase (NOS), an inducible form that can be activated by cytokines such as tumor necrosis factor α (TNFα). We evaluated NO plasmatic levels, endothelial damage markers such as von Willebrand factor (vWF), platelet activation, soluble P-selectin (sP-Sel), TNFα levels, insulinaemia (I), glycosylated haemoglobin (HbA1c), glycaemia and blood pressure in 32 hypertensive diabetic type II patients (Group A), 37 hypertensive patients (Group B) and 35 healthy subjects (Group C) matched in sex, age, body mass index and dietary habits. The level of I was increased in patients compared to the controls and correlated with their NO levels. vWF plasmatic levels were increased in Group A compared to Groups B and C. We also found significant differences in platelet activation among all the groups. In diabetic patients, increased NO levels correlated with TNFα, HbA1c and platelet activation showed greater endothelial damage than in Group B. These parameters described a prothrombotic state associated with an insulin resistance state, an increased vWF release, raised sP-Sel and TNFα levels and, maybe, low NO bioavailability, which could lead to a higher risk of development of thrombotic events in hypertensive diabetic patients (Group A) than in the hypertensive patients in Group B. © 2001 Elsevier Science Ltd. |
|---|---|
| Bibliografía: | Cines, D.B., Polak, E.S., Buck, C.A., Loscalzo, J., Zimmerman, G.A., McEver, R.P., Pober, J.S., Stern, D.M., Endothelial cells in physiology and in the pathophysiology of vascular disorders (1998) Blood, 91, pp. 3527-3561 DeMeyer, G.R.Y., Herman, A.G., Vascular endothelial dysfunction (1997) Prog Cardiovasc Dis, 39, pp. 325-342 Moncada, S., Higgs, A., The L-arginine-nitric oxide pathway (1993) N Engl J Med, 27, pp. 2002-2011 Stoiser, B., Maca, T., Thalammer, F., Hollenstein, U., El Menyawi, I., Burgmann, H., Serum nitrate concentration in patients with peripheral arterial occlusive disease (1999) Vasa, 28, pp. 181-184 Ferlito, S., Gallina, M., Nitrite plasma levels in type 1 and 2 diabetes with and without complications (1998) Panminerva Med, 40, pp. 304-308 Celermajer, D.S., Endothelial dysfunction: Does it matter? Is it reversible? (1997) JACC, 30, pp. 325-333 Shimokawa, H., Endothelial dysfunction in hypertension (1998) J Atheroscler Thromb, 4, pp. 118-127 Stehouwer, C.D.A., Schaper, N.C., The pathogenesis of vascular complications of diabetes mellitus: One voice or many? (1996) Eur J Clin Invest, 26, pp. 535-543 Schmidt, A., Hori, O., Brett, J., Cellular receptors for AGEs: Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis on vascular lesions (1994) Arterioscler Thromb, pp. 1521-1528 Ferrannini, E., Haffner, S.M., Stern, M.P., Essential hypertension: An insulin resistence state (1990) Cardiovasc Pharmacol, 15, pp. 18-25 Ferrannini, E., Buzzigoli, G., Bonadonna, R., Insulin resistance in essential hypertension (1987) N Engl J Med, 317, pp. 350-357 DeFronzo, R.A., Ferrannini, E., Insulin resistance: A multifacetic syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease (1991) Diabetes Care, 14, pp. 173-194 Tooke, J.E., Hannemann, M.M., Adverse endothelial function and the insulin resistance syndrome (2000) J Intern Med, 247, pp. 425-431 Tachoepe, D., Rolsen, P., Schripper, B., Platelets in diabetes: The role in the hemostatic regulation in atherosclerosis (1993) Semin Thromb Haemostasis, 19, pp. 122-128 Mc Ever, P.R., GMP-140: A receptor for neutrophils and monocytes on activated platelets and endothelium (1991) J Cell Biochem, 45, pp. 156-161 Furie, B., Furie, B.C., The Molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: Role of P-selectin and the P-selectin ligand PSGL-1 (1995) Thromb Haemostasis, 74, pp. 224-227 Fijnheer, R., Frijns, C.J., Korteweg, J., Rommes, H., Peters, J.H., Sixma, J.J., Nieuwenhuis, H.K., The origin of P-selectin as a circulating plasma protein (1997) Thromb Haemostasis, 77, pp. 1081-1085 Blann, A.D., Lip, G.Y.H., Beevers, D.G., McCollum, C.N., Soluble P-selectin in atherosclerosis: A comparison with endothelial cell and platelet markers (1997) Thromb Haemostasis, 77, pp. 1077-1080 Lip, G., Blann, A., Von Willebrand factor: A marker of endothelial dysfunction in vascular disorders? (1997) Cardiovasc Res, 34, pp. 255-265 Mantovani, A., Bussolino, F., Dejana, E., Cytokine regulation of enthotelial cell function (1992) FASEB J, 6, pp. 2591-2599 The sixth report of the Joint National Commmittee on Detection, Evaluation and Treatment of High Pressure (JNC VI) (1997) Arch Intern Med, 157, pp. 2413-2446 Moshage, H., Kok, B., Huizenga, J.R., Jansen, P.L., Nitrite and nitrate determination in plasma: A critical evaluation (1995) Clin Chem, 41, pp. 892-896 Michelson, A.D., Platelet activation by thrombine can be directely measured in whole blood through the use of peptide GPRP and flow cytometry: Methods and clinical applications (1994) Blood Coagulation Fibrinolysis, 5, pp. 121-131 Brownlee, M., Advanced protein glycosylation in diabetes and aging (1995) Annu Rev Med, 46, pp. 223-234 Bucala, R., Tracey, K.J., Cerami, A., Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes (1991) J Clin Invest, 87, pp. 432-438 Kaplan, N.M., Primary hypertension: Pathogenesis (1998) Clinical hypertension. 7th ed., pp. 41-99. , Kaplan NM, editor. Baltimore, MD: Williams and Wilkins Hausberg, M., Hoffman, R.P., Somers, V.K., Contrasting autonomic and hemodinamic effects of insulin in healthy elderly versus young subjects (1997) Hypertension, 29, pp. 700-705 Cleland, S.J., Petrie, J.R., Small, M., Elliott, H.L., Connell, J.M., Insulin action is associated with endothelial function in hypertension and type 2 diabetes (2000) Hypertension, 35, pp. 507-511 Radomski, M.W., Moncada, S., Regulation of vascular homeostasis by nitric oxide (1993) Thromb Haemostasis, 70, pp. 36-41 Li, H., Fostermann, U., Nitric oxide in the pathogenesis of vascular disease (2000) J Pathol, 190, pp. 244-254 Wu, C.-C., Yen, M.-H., Higher level of plasma nitric oxide in spontaneously hypertensive rats (1999) Am J Hypertens, 12, pp. 476-482 Nava, E., Farré, A., Moreno, C., Casado, S., Moreau, P., Cosentino, F., Lüscher, T.F., Alterations to the nitric oxide pathway in the spontaneously hypertensive rat (1998) J Hypertens, 16, pp. 609-615 Anggard, E., Nitric oxide: Mediator, murderer and medicine (1994) Lancet, 343, pp. 1199-1206 Kodja, G., Harrison, D., Interaction between NO and reactive oxygen species: Pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure (1999) Cardiovasc Res, 43, pp. 562-571 Vallejo, S., Angulo, J., Periro, C., Nevado, J., Sanchez-Ferrer, A., Petidier, R., Sanchez-Ferrer, C.F., Rodriguez-Manas, L., Highly glycated oxyhaemoglobin impairs nitric oxide relaxations in human mesenteric microvessels (2000) Diabetologia, 43, pp. 83-90 |
| ISSN: | 00493848 |
| DOI: | 10.1016/S0049-3848(01)00237-7 |